# CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation

> **NCT06762964** · PHASE2 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 27 (estimated)

## Conditions studied

- Fontan Circulation
- Single Ventricle Heart Disease
- HFpEF - Heart Failure With Preserved Ejection Fraction

## Interventions

- **DRUG:** Dapagliflozin tablet
- **DRUG:** Placebo Tablet

## Key facts

- **NCT ID:** NCT06762964
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-16
- **Primary completion:** 2027-02
- **Final completion:** 2027-02
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06762964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06762964, "CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06762964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*